Erratum: Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors (International Journal of Cancer (2013)132:4(795-806) 10.1002/ijc.27730);Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors

International Journal of Cancer

Volumn 132, Issue 4, 2012, Pages 795-806

  Chadalapaka, Gayathri ^a   Jutooru, Indira ^a   Sreevalsan, Sandeep ^a   Pathi, Satya ^a   Kim, Kyounghyun ^b   Chen, Candy ^c   Crose, Lisa ^c   Linardic, Corinne ^c   Safe, Stephen ^a,b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

downregulation; RMS cells; Sp proteins; tolfenamic acid

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; SCATTER FACTOR RECEPTOR; SOMATOMEDIN RECEPTOR; TOLFENAMIC ACID; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; TRANSCRIPTION FACTOR SP4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C MET GENE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; CXCR4 GENE; DOWN REGULATION; FEMALE; GENE; GENETIC REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INSULIN LIKE GROWTH FACTOR RECEPTOR GENE; METASTASIS INHIBITION; MOUSE; MUSCLE TISSUE; NONHUMAN; PDGFR ALPHA GENE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RHABDOMYOSARCOMA; RNA INTERFERENCE;

EID: 84871366640     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29551     Document Type: Erratum

References (50)

1. Paulino AC, Okcu MF,. Rhabdomyosarcoma. Curr Probl Cancer 2008; 32: 7-34.
2. Ries LAG, Smith MA, Gurney JG, et al. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. NIH Publication No. 99-4649 National Institutes of Health, 1999.
3. Grufferman S, Schwartz AG, Ruymann FB, et al. Parents' use of cocaine and marijuana and increased risk of rhabdomyosarcoma in their children. Cancer Causes Control 1993; 4: 217-24.
4. Hicks N, Zack M, Caldwell GG, et al. Childhood cancer and occupational radiation exposure in parents. Cancer 1984; 53: 1637-43. (Pubitemid 14127498)
5. Barr FG, Galili N, Holick J, et al. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993; 3: 113-7. (Pubitemid 23079791)
6. Davis RJ, D'Cruz CM, Lovell MA, et al. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994; 54: 2869-72. (Pubitemid 24187765)
7. Barber TD, Barber MC, Tomescu O, et al. Identification of target genes regulated by PAX3 and PAX3-FKHR in embryogenesis and alveolar rhabdomyosarcoma. Genomics 2002; 79: 278-84. (Pubitemid 34211935)
8. Khan J, Bittner ML, Saal LH, et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci U S A 1999; 96: 13264-9.
9. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 2002; 20: 2672-9. (Pubitemid 34575640)
10. Maurer HM,. The Intergroup Rhabdomyosarcoma Study (NIH): objectives and clinical staging classification. J Pediatr Surg 1975; 10: 977-78.
11. Maurer HM, Moon T, Donaldson M, et al. The intergroup rhabdomyosarcoma study: a preliminary report. Cancer 1977; 40: 2015-26. (Pubitemid 8239684)
12. Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003; 21: 78-84.
13. Abdelrahim M, Baker CH, Abbruzzese JL, et al. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 2006; 98: 855-68. (Pubitemid 43923442)
14. Chintharlapalli S, Papineni S, Ramaiah SK, et al. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 2007; 67: 2816-23. (Pubitemid 46548971)
15. Papineni S, Chintharlapalli S, Abdelrahim M, et al. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 2009; 30: 1193-201.
16. Chadalapaka G, Jutooru I, Chintharlapalli S, et al. Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res 2008; 68: 5345-54.
17. Chintharlapalli S, Papineni S, Abdelrahim M, et al. Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3,11-dioxo-18beta- olean-1,12-dien-30-oate in colon cancer cells. Int J Cancer 2009; 125: 1965-74.
18. Mertens-Talcott SU, Chintharlapalli S, Li X, et al. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res 2007; 67: 11001-11. (Pubitemid 350145930)
19. Jutooru I, Chadalapaka G, Sreevalsan S, et al. Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. Exp Cell Res 2010; 316: 2174-88.
20. Abdelrahim M, Baker CH, Abbruzzese JL, et al. Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res 2007; 67: 3286-94. (Pubitemid 46724867)
21. Chadalapaka G, Jutooru I, Burghardt R, et al. Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. Mol Cancer Res 2010; 8: 739-50.
22. Abdelrahim M, Smith R, 3rd, Burghardt R, et al. Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res 2004; 64: 6740-9. (Pubitemid 39297937)
23. Jutooru I, Chadalapaka G, Abdelrahim M, et al. Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a. Mol Pharmacol 2010; 78: 226-36.
24. Jutooru I, Chadalapaka G, Lei P, et al. Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J Biol Chem 2010; 285: 25332-44.
25. Taulli R, Scuoppo C, Bersani F, et al. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 2006; 66: 4742-9.
26. Yu SJ, Zheng L, Ladanyi M, et al. Sp1-mediated transcriptional control of fibroblast growth factor receptor 4 in sarcomas of skeletal muscle lineage. Clin Cancer Res 2004; 10: 6750-8. (Pubitemid 39346573)
27. Linardic CM, Naini S, Herndon JE, 2nd, et al. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer Res 2007; 67: 6691-9. (Pubitemid 47105515)
28. Rimm DL, Camp RL, Charette LA, et al. Tissue microarray: a new technology for amplification of tissue resources. Cancer J 2001; 7: 24-31.
29. Kendall SD, Linardic CM, Adam SJ, et al. A network of genetic events sufficient to convert normal human cells to a tumorigenic state. Cancer Res 2005; 65: 9824-8. (Pubitemid 41541460)
30. Naini S, Etheridge KT, Adam SJ, et al. Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Res 2008; 68: 9583-8.
31. Saffer JD, Jackson SP, Thurston SJ,. SV40 stimulates expression of the transacting factor Sp1 at the mRNA level. Genes Dev 1990; 4: 659-66.
32. Kennett SB, Udvadia AJ, Horowitz JM,. Sp3 encodes multiple proteins that differ in their capacity to stimulate or repress transcription. Nucleic Acids Res 1997; 25: 3110-7. (Pubitemid 27331406)
33. Kennett SB, Moorefield KS, Horowitz JM,. Sp3 represses gene expression via the titration of promoter-specific transcription factors. J Biol Chem 2002; 277: 9780-9. (Pubitemid 34968081)
34. Taniguchi E, Nishijo K, McCleish AT, et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 2008; 27: 6550-60.
35. Libura J, Drukala J, Majka M, et al. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood 2002; 100: 2597-606.
36. Strahm B, Durbin AD, Sexsmith E, et al. The CXCR4-SDF1alpha axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma. Clin Exp Metastasis 2008; 25: 1-10. (Pubitemid 351191222)
37. Pathi SS, Jutooru I, Chadalapaka G, et al. GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA- 27a: ZBTB10-specificity protein pathway. Mol Cancer Res 2011; 9: 195-202.
38. Bouwman P, Philipsen S,. Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol 2002; 195: 27-38. (Pubitemid 35287159)
39. Black AR, Black JD, Azizkhan-Clifford J,. Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001; 188: 143-60. (Pubitemid 32622905)
40. Ammendola R, Mesuraca M, Russo T, et al. Sp1 DNA binding efficiency is highly reduced in nuclear extracts from aged rat tissues. J Biol Chem 1992; 267: 17944-8.
41. Adrian GS, Seto E, Fischbach KS, et al. YY1 and Sp1 transcription factors bind the human transferrin gene in an age-related manner. J Gerontol A Biol Sci Med Sci 1996; 51: B66-75. (Pubitemid 26026965)
42. Oh JE, Han JA, Hwang ES,. Downregulation of transcription factor, Sp1, during cellular senescence. Biochem Biophys Res Commun 2007; 353: 86-91. (Pubitemid 46001376)
43. Jiang NY, Woda BA, Banner BF, et al. Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2008; 17: 1648-52.
44. Wang L, Wei D, Huang S, et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 2003; 9: 6371-80. (Pubitemid 38031822)
45. Lou Z, O'Reilly S, Liang H, et al. Down-regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits tumor formation. Cancer Res 2005; 65: 1007-17. (Pubitemid 40216463)
46. Mayeenuddin LH, Yu Y, Kang Z, et al. Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x(L). Oncogene 2010; 29: 6367-77.
47. Wan X, Shen N, Mendoza A, et al. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 2006; 8: 394-401. (Pubitemid 43830746)
48. Haliotis FA, Tzortzinis AA, Papanastasiou DA,. Use of tolfenamic acid in febrile children with and without glucose-6-phosphate dehydrogenase deficiency. Int J Clin Pharmacol Ther 1997; 35: 103-6. (Pubitemid 27129614)
49. Lascelles BD, Court MH, Hardie EM, et al. Nonsteroidal anti-inflammatory drugs in cats: a review. Vet Anaesth Analg 2007; 34: 228-50. (Pubitemid 46912061)
50. Stein U, Arlt F, Smith J, et al. Intervening in beta-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis. Neoplasia 2011; 13: 131-44.